Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04855526
Other study ID # R-HHC-2019-0137
Secondary ID 126663
Status Not yet recruiting
Phase Early Phase 1
First received
Last updated
Start date April 1, 2022
Est. completion date June 30, 2022

Study information

Verified date January 2022
Source Hartford Hospital
Contact Chelsea N Meagher, BA
Phone 860-545-7106
Email chelsea.meagher@hhchealth.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Memory deficits are one of the most consistently observed cognitive effects of marijuana use. There is evidence that some decrements attributable to the primary psychoactive ingredient, delta-9-tetrahydrocannabinol (THC), may be attenuated by cannabidiol (CBD). This study will help us learn more about the relationship between THC and CBD consumption with memory processes. A combination of MRI and neuropsychological tests (which are computer and paper/pencil tasks) will be used to measure the neurocognitive and behavioral impacts of THC and CBD use.


Description:

With increased legalization and medicalization of marijuana (MJ), there is an urgent need to understand the acute effects of use. One of the most consistently observed cognitive outcomes associated with MJ use is memory dysfunction, which may have a substantial impact on daily life in individuals using MJ for recreational or medicinal purposes. Notably, there are numerous preparations of MJ with varying proportions of cannabinoids, which may differ in behavioral and cognitive effects. For instance, there is emerging evidence that acute administration of delta-9-tetrahydrocannabinol (THC), the main psychoactive constituent of MJ, hinders memory and reduces prefrontal and hippocampal functional magnetic resonance imaging (fMRI) activation, but cannabidiol (CBD) may mitigate some of these impairments. Given the role of glutamate in learning and memory, the investigators suggest that these effects may be subserved, in part, by glutamatergic mechanisms. The investigators will use magnetic resonance spectroscopy (MRS) to non-invasively measure glutamate in order to explore the neurochemical underpinnings of memory-related fMRI response changes following acute administration of THC and CBD in a randomized, double-blind, placebo-controlled, cross-over design. A total of 9 healthy participants ages 18-40 will be enrolled. Participants will first undergo one screening visit (~4 hours), comprising informed consent, assessment of health history, psychiatric diagnoses, cognitive function, and substance use history, and a structural MRI session. This will be followed by 3 separate MJ dose visits (~4 hours each), at which participants will complete neuroimaging after administration of one of 3 preparations of vaporized MJ in a randomized, counterbalanced, double-blinded fashion: 1) high THC and no CBD (THC), 2) high THC and high CBD (THC+CBD), and 3) no THC and no CBD (placebo MJ). As in the investigator's ongoing studies, bulk MJ plant material will be provided by the National Institute on Drug Abuse. MJ dose visits will comprise MJ administration, blood collection, MRS/fMRI scan, subjective reports, and a brief cognitive assessment.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 9
Est. completion date June 30, 2022
Est. primary completion date June 30, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria: - Right-handed - Prior MJ users (has used MJ at least once in the past year, but no more than 1x/month in the past 12 months) - Medically healthy (as determined by medical history and treatment) - Adequate comprehension of English in order to complete study materials - Acceptable birth control method for women (i.e., no copper IUD or any device that is not MRI safe) Exclusion Criteria: - Participant currently uses psychoactive medications or substances - Psychiatric diagnoses (determined by DSM-V) - Participant heavily or regularly uses MJ (more than 1x/month in the past year) - Current or past substance dependence (including MJ) - Positive urine toxicology screens - Positive pregnancy screens - MRI contraindications (e.g., heart pacemaker)

Study Design


Intervention

Drug:
High THC/No CBD Marihuana
high THC (65 mg THC) and no CBD (0 mg CBD)
High THC/High CBD Marihuana
high THC (65 mg THC) and high CBD (50 mg CBD)
No THC/No CBD Marihuana
no THC (0 mg THC) and no CBD (0 mg CBD); placebo drug

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Hartford Hospital Yale University

Outcome

Type Measure Description Time frame Safety issue
Primary fMRI response Blood oxygen level dependent functional magnetic resonance imaging (fMRI) response during the relational and item specific encoding task. fMRI response will be evaluated during the encoding phase (relational vs. item encoding), item recognition phase (hits vs. misses for item-specific encoding, and hits vs. misses for relational encoding), and associative recognition phase (hits vs. misses). approximately 1 hour following drug administration
Primary Glutamate Magnetic resonance spectroscopy (MRS)-acquired glutamate containing compounds (Glx). approximately 1 hour following drug administration
Secondary HVLT-R performance The Hopkins Verbal Learning Test-Revised will ascertain verbal list learning and immediate and delayed recall (~15min); alternate forms have been validated, and the order of versions participants receive will be randomized Approximately 2.50 hours after drug administration
Secondary Performance on CHARLIE cognitive task This is a computer-based cognitive battery that administers the Digit Span and Letter/Number Sequencing Test (working memory) and the Digit Symbol Coding test (processing speed). It should take about 10 minutes to complete. Approximately 3.00 hours after drug administration
Secondary Blood THC and CBD concentration testing A blood sample will be taken once per dose visit to assess the concentration of the following metabolites in ng/mL: delta-9-tetrahydrocannabinol, 11-hydroxy-tetrahydrocannabinol, 11-Nor-9-Carboxy-tetrahydrocannabinol (THCCOOH), tetrahydrocannabinol-Glucuronide, THCCOOH-Glucuronide, cannabinol (CBN), and cannabidiol (CBD). Immediately after drug administration (~0.25 hours after drug administration)
Secondary Subjective effects on drug effects questionnaire This self-report will be used to assess subjective reports every 60 minutes throughout the dose visit days. These subjective ratings will be obtained using rapidly completed Visual Analog Scales (VASs) scored on a 0-100 scale. Items include: Do you feel a drug effect right now?, Are you high right now?, Do you dislike any of the effects you are feeling right now?, Do you like any of the effects you are feeling right now? and Would you like more of the drug you took, right now? Post drug administration at: 0.00 hours (immediately after); 1.0 hours; 2.0 hours; 3.0 hours
See also
  Status Clinical Trial Phase
Completed NCT03253926 - Effect of Lorcaserin on Cannabis Withdrawal and Self-administration Phase 1/Phase 2
Completed NCT04060602 - Personalized Feedback Intervention to Reduce Risky Cannabis Use. N/A
Completed NCT01212081 - Assessment of Cannabis Craving in Schizophrenia Using Virtual Reality
Recruiting NCT04988490 - Quantification of Cannabinoids and Comparison to Post-Surgical Pain Medication Requirements and Surgical Outcomes
Recruiting NCT05188404 - Aging and Marijuana: Benefits, Effects, and Risks
Completed NCT03662737 - VRT as a Biomarker of Cerebellar Dysfunction in Chronic Cannabis Use
Not yet recruiting NCT05999383 - Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration Phase 2
Terminated NCT04436055 - Intergenerational Effects of Paternal Periconceptional Cannabis and Other Drug Use (EPIC)
Active, not recruiting NCT04374773 - Effects of Pregnancy-associated Hormones on THC Metabolism in Women Phase 4
Completed NCT04316741 - Brief Intervention Combined With Health Coaching Via Social Media for Cannabis Use N/A
Recruiting NCT05396638 - Characterization of Endocannabinoid and Endogenous Opioid Levels in Adolescents With Cannabis Use Disorder N/A
Recruiting NCT05309226 - Cannabis Use in Pregnancy and Downstream Effects on Maternal and Infant Health
Recruiting NCT03859089 - Cannabis for Opioid Substitution Trial
Recruiting NCT05849636 - Alerta Cannabis: Evaluation of Web-based Tailored Intervention N/A
Enrolling by invitation NCT05521321 - Feasibility and Acceptability of the Cannabis Awareness and Prevention Toolkit N/A
Recruiting NCT05119244 - Environment and Lung Cancer N/A
Recruiting NCT04841655 - Tobacco Cessation Among Smokers Under Alcohol and/or Cannabis Treatment
Terminated NCT04100590 - Eye Tracking as a Biomarker of Cannabis Effects Phase 2
Completed NCT05167097 - Mindsets and the Effectiveness of a Brief Intervention - Replication N/A
Recruiting NCT04114903 - Exploring the Anti-inflammatory Properties of Cannabis and Their Relevance to Insulin Sensitivity